TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25542273

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive interpersonal style
Number of subjects: 705

Group type: COMPARATOR
Intervention: Controlling interpersonal style
Number of subjects: 705
Study: 22882381

Group type: EXPERIMENTAL
Intervention: Haemonetics cardioPAT system
Number of subjects: 1047
Study: 21299293

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (C‐STOP)
Number of subjects: 1189
Study: 19842242

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI)
Number of subjects: 50
Study: 16785477

Group type: EXPERIMENTAL
Intervention: Verapamil sustained-release or atenolol-based strategy
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Diastolic pressure below 119/84 mm Hg
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: History of revascularization
Number of subjects: 22576
Study: 14555255

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 10983646

Group type: EXPERIMENTAL
Intervention: d4T + 3TC + IDV
Number of subjects: 204

Group type: COMPARATOR
Intervention: ZDV + 3TC + IDV
Number of subjects: 204
Study: 9097197

Group type: EXPERIMENTAL
Intervention: Family-state induction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neutral-state induction
Number of subjects: 64
Study: 8227900

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at low-dose (0.25 microgram/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at high-dose (2.0 micrograms/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 16
Study: 3763935

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 0
Study: 28415143

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) measured by VO2max
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 39
Study: 26610389

Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 173

Group type: COMPARATOR
Intervention: Spiral-notebook guide
Number of subjects: 173
Study: 24632572

Group type: EXPERIMENTAL
Intervention: LMA-S
Number of subjects: 60

Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 60
Study: 21538680

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 210
Study: 20534644

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 18773725

Group type: EXPERIMENTAL
Intervention: Correspondence matching in long-range motion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15001596

Group type: EXPERIMENTAL
Intervention: nurse-monitoring
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: marker-monitoring
Number of subjects: 75

Group type: COMPARATOR
Intervention: no monitoring
Number of subjects: 75
Study: 11331169

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HES groups
Number of subjects: 60
Study: 9150068

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 23

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 23
Study: 7950183

Group type: EXPERIMENTAL
Intervention: Combined therapy of traditional Chinese medicine and Western medicine (TCM-WM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Western medicine only (WM)
Number of subjects: 38
Study: 3107602

Group type: EXPERIMENTAL
Intervention: lysine acetyl salicylate (LAS) 13 mg kg‐1 i.v. 3 min before suxamethonium
Number of subjects: 20

Group type: COMPARATOR
Intervention: atracurium 0.09 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30027568

Group type: EXPERIMENTAL
Intervention: Rehabilitation services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher socioeconomic participants
Number of subjects: 0
Study: 27291448

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 24
Study: 25903109

Group type: EXPERIMENTAL
Intervention: Serelaxin (RELAX group)
Number of subjects: 581

Group type: COMPARATOR
Intervention: EAHFE-RELAX groups
Number of subjects: 581
Study: 23660180

Group type: EXPERIMENTAL
Intervention: IV isotonic sodium bicarbonate
Number of subjects: 8680

Group type: COMPARATOR
Intervention: IV isotonic sodium chloride
Number of subjects: 8680

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC)
Number of subjects: 8680

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8680
Study: 20950456

Group type: EXPERIMENTAL
Intervention: New DTPw-HBV/Hib vaccine
Number of subjects: 585

Group type: COMPARATOR
Intervention: Tritanrix™-HBV/Hib (Control)
Number of subjects: 585
Study: 18242706

Group type: EXPERIMENTAL
Intervention: Treatment of unruptured aneurysms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subgroup statistics from observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial
Number of subjects: 0
Study: 17012640

Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Russian current
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monophasic pulsed currents
Number of subjects: 32
Study: 14572851

Group type: EXPERIMENTAL
Intervention: Satisfaction with healthcare
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient satisfaction surveys
Number of subjects: 30
Study: 10933737

Group type: EXPERIMENTAL
Intervention: Stent plus abciximab
Number of subjects: 140

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 140
Study: 8757567

Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy (20 U/kg body weight, subcutaneously, three times a week for 6 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (sham treatment)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 1424602

Group type: EXPERIMENTAL
Intervention: Chloroform/Methanol (CM) application
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ether/Acetone (EA) application
Number of subjects: 11
Study: 2864775

Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aceclidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol and aceclidine combination
Number of subjects: 0
Study: 31317553

Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy with bilateral practice (RTBP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual task-specific training facilitated by therapists (Control)
Number of subjects: 43
Study: 30368373

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 26885934

Group type: EXPERIMENTAL
Intervention: Self-monitoring exercise intervention (SM condition)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care exercise program (CON condition)
Number of subjects: 13
Study: 25260762

Group type: EXPERIMENTAL
Intervention: Free-media referrals
Number of subjects: 5008

Group type: EXPERIMENTAL
Intervention: Paid-media referrals
Number of subjects: 5008

Group type: EXPERIMENTAL
Intervention: Free-to-read print advertisements
Number of subjects: 5008

Group type: COMPARATOR
Intervention: Fax recruits
Number of subjects: 5008

Group type: COMPARATOR
Intervention: In-clinic recruits
Number of subjects: 5008
Study: 22489903

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus moderate-to-high-intensity endurance training (MeDE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mediterranean diet (MeD)
Number of subjects: 45
Study: 20351325

Group type: EXPERIMENTAL
Intervention: 80 IU/m(2) of pegylated arginine deiminase (ADI) weekly for up to 6 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 160 IU/m(2) of pegylated arginine deiminase (ADI) weekly for up to 6 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pegylated arginine deiminase (ADI)
Number of subjects: 80
Study: 17506785

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (10-400 mg single doses or 50-400 mg three times daily for 6 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15474697

Group type: EXPERIMENTAL
Intervention: Statin treatment started at least 3 days before the procedure
Number of subjects: 451

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 451
Study: 11486456

Group type: EXPERIMENTAL
Intervention: 1% lanoconazole cream (Astat) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with 1% lanoconazole cream and 10% urea ointment (Pastaron)
Number of subjects: 0
Study: 9743849

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol 9 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol 27 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7920872

Group type: EXPERIMENTAL
Intervention: WT4EE
Number of subjects: 118

Group type: COMPARATOR
Intervention: C4EE
Number of subjects: 118
Study: 2899062

Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (0.17 mg/kg fat free mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ro 16-8714
Number of subjects: 12
Study: 27387513

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study: 27597276

Group type: EXPERIMENTAL
Intervention: TAS-102 (35mg/m²/dose twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (topotecan or amrubicin)
Number of subjects: 18
Study: 25911121

Group type: EXPERIMENTAL
Intervention: IMF-screws (IMFS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: arch bars
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IMF-screws (IMFS) and arch bars
Number of subjects: 50
Study: 24044216

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a combined with entecavir for 12 weeks, then Peginterferon alpha‐2a monotherapy for 36 weeks (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peginterferon alpha‐2a monotherapy for 48 weeks (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Entecavir monotherapy for more than 48 weeks (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a combined with entecavir (Group C)
Number of subjects: 60
Study: 20307262

Group type: EXPERIMENTAL
Intervention: SCION‐PAIN program (additional to standard pain treatment)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study: 17951035

Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (zero-dose)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (low-dose)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (middle-dose)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (high-dose)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Ordinary coffee (control)
Number of subjects: 203
Study: 16750285

Group type: EXPERIMENTAL
Intervention: Alveolar vaccination (controlled inhalation of Pneumovax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchial vaccination (controlled inhalation of Pneumovax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intramuscular vaccination (control group)
Number of subjects: 0
Study: 12860336

Group type: EXPERIMENTAL
Intervention: rec‐FSH
Number of subjects: 31

Group type: COMPARATOR
Intervention: urinary FSH (u‐FSH)+hMG
Number of subjects: 31

Group type: COMPARATOR
Intervention: u‐FSH only
Number of subjects: 31
Study: 15077096

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 249

Group type: COMPARATOR
Intervention: Stenting after predilatation
Number of subjects: 249
Study: 10661784

Group type: EXPERIMENTAL
Intervention: Reciprocating gait orthosis (RGO)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hip guidance orthosis (HGO)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both HGO and RGO
Number of subjects: 22
Study: 7747686

Group type: EXPERIMENTAL
Intervention: Octreotide, 500 micrograms/24 hours subcutaneously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (normal subjects matched for sex and age)
Number of subjects: 10
Study: 2127537

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone with low-dose flecainide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flecainide and encainide
Number of subjects: 0
Study: 7248985

Group type: EXPERIMENTAL
Intervention: iv vincristine, intrathecal methotrexate, and intrathecal hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28330831

Group type: EXPERIMENTAL
Intervention: iMIND (n=604)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: iCBT (n=651)
Number of subjects: 1255
Study: 25609761

Group type: EXPERIMENTAL
Intervention: Repeated short-answer quizzing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Repeated studying
Number of subjects: 35

Group type: COMPARATOR
Intervention: No further exposure
Number of subjects: 35
Study: 24195862

Group type: EXPERIMENTAL
Intervention: Innovative Tai Chi Rehabilitation Program (ITCRP) - tai chi two or three times a week for 6 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group - health education
Number of subjects: 140
Study: 21341932

Group type: EXPERIMENTAL
Intervention: Fast track diagnosis and treatment program for CRC
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (habitual pathways)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both pathways (fast track and control)
Number of subjects: 156
Study: 19808342

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290

Group type: COMPARATOR
Intervention: Control (no trandolapril)
Number of subjects: 8290
Study: 17996561

Group type: EXPERIMENTAL
Intervention: Candesartan (titrated to a target of 32 mg once daily)
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 15037057

Group type: EXPERIMENTAL
Intervention: Emotional narratives in AD patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Emotional narratives in control participants
Number of subjects: 80
Study: 11417441

Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 7
Study: 9603181

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7826795

Group type: EXPERIMENTAL
Intervention: Coiled-tipped catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard straight-tipped catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: 32-gauge microcatheter (TFX)
Number of subjects: 0
Study: 2843066

Group type: EXPERIMENTAL
Intervention: 0.75 mg morphine sulfate intrathecally
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.75 mg morphine sulfate intramuscularly (control)
Number of subjects: 20
Study: 31512072

Group type: EXPERIMENTAL
Intervention: UV irradiated surface-treated implants
Number of subjects: 180

Group type: COMPARATOR
Intervention: Original surface implants (control)
Number of subjects: 180
Study: 31346895

Group type: EXPERIMENTAL
Intervention: Antiseptic dressing group (3M® Tegaderm® CHG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (standard drain care)
Number of subjects: 104
Study: 28921814

Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg/day for 10 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 18
Study: 25528200

Group type: EXPERIMENTAL
Intervention: Carvedilol 2.5 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Carvedilol 5 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Carvedilol 20 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Carvedilol (all doses)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 117
Study: 24088722

Group type: EXPERIMENTAL
Intervention: Short sleep (4 h/night)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Habitual sleep (8 h/night)
Number of subjects: 10
Study: 21196829

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Articaine 4% with epinephrine 1:200 000
Number of subjects: 0
Study: 19296355

Group type: EXPERIMENTAL
Intervention: Nonrandomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potentially effective treatments
Number of subjects: 0
Study: 17464603

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (group F)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Peri‐ and intraarticular infiltration with 300 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine (group I)
Number of subjects: 80
Study: 15111692

Group type: EXPERIMENTAL
Intervention: Fully automated, normalized technique with full brain coverage (SIENA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semiautomated, nonnormalized technique with partial brain coverage
Number of subjects: 0
Study: 12297933

Group type: EXPERIMENTAL
Intervention: Incised mesh
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non-incised mesh
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Clip fixation
Number of subjects: 360

Group type: COMPARATOR
Intervention: Suturing the mesh
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Repair of Nyhus type II hernias
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Duplex flow examination of testicular vessels
Number of subjects: 360
Study: 9797056

Group type: EXPERIMENTAL
Intervention: Toothpick method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bass method
Number of subjects: 20
Study: 7611638

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2236584

Group type: EXPERIMENTAL
Intervention: Portable, head-mounted phototherapy device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard light box
Number of subjects: 0
Study: 340005

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (nicoumalone) treatment
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-dose heparin calcium
Number of subjects: 145

Group type: COMPARATOR
Intervention: Subcutaneous saline
Number of subjects: 145
Study: 30942036

Group type: EXPERIMENTAL
Intervention: Lieque (LU 7) acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Jingqu (LU 8) acupuncture
Number of subjects: 36
Study: 26832859

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI) - 32 Gy in eight fractions over 5-6 days
Number of subjects: 183

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 50 Gy in fractions of 2 Gy for 5 weeks
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 183
Study: 25353078

Group type: EXPERIMENTAL
Intervention: Vibration exercise warm-up (VbX)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Deadlift-specific warm-up (DL-WU)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (body-weight squats without vibration)
Number of subjects: 3
Study: 21349113

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 24
Study: 19557959

Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (ILMA)
Number of subjects: 60
Study: 16675939

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 mg kg(‐1) h(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 2‐3 mg kg(‐1) h(‐1)
Number of subjects: 40
Study: 15251635

Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion for at least 24 hours followed by long-term subcutaneous insulin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin treatment in patients without prior insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11744471

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 3 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9285267

Group type: EXPERIMENTAL
Intervention: Anagrams of neutral, food, and threat words (Study 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anagrams of words reflecting physical threat, self-directed ego threat, and ego threat directed from others (Study 2)
Number of subjects: 80
Study: 8440854

Group type: EXPERIMENTAL
Intervention: Various intervention strategies tested at eight FICSIT sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared descriptive (risk-adjustment) measures and outcome measures
Number of subjects: 0
Study: 3325220

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multiple insulin injections (MII) using a pen injector
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multiple insulin injections (MII)
Number of subjects: 20